EMA/EMI for Psychiatrically Hospitalized Emerging Adults Who Drink to Cope

July 30, 2026 updated by: Butler Hospital

Project CHOICE: Developing a Personalized-Feedback EMA/EMI Intervention for Emerging Adults Leaving Psychiatric Partial Hospitalization

The goal of this proposed study is to evaluate an ecological momentary assessment plus an ecological momentary intervention (EMA+EMI) for emerging adults in a psychiatric partial hospitalization program who drink to cope with negative affect (NA) as compared to personalized feedback only. This intervention combines a personalized feedback intervention (PFI) with EMA technology and tailored EMI text messaging (PFICope+EMI). PFICope+EMI not only aims to reduce drinking to cope, but also alcohol use and NA. This study consists of a 6-week randomized controlled treatment trial to test the PFIcope+EMI intervention as compared to personalized normative feedback only (PNF).

Study Overview

Detailed Description

Given the relationship between mental health and alcohol problems, there is a need to address comorbidity among emerging adults (EAs) with anxiety and/or depression. The weeks after psychiatric hospitalization are a risky time for problematic alcohol use and recurrence of psychiatric symptoms. The delivery of tailored, coping skills-based, real-time messages could have a significant impact on problematic drinking and depression/anxiety outcomes by reducing the likelihood that an individual drinks to cope with NA.

The aim of this study is to test a 6-week PFIcope+EMI intervention as compared to personalized normative feedback only (PNF) for EA in a partial hospitalization program who drink to cope and binge drink (n=60). The PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported). The Personalized Normative Feedback condition (PNF) will receive a personalized normative feedback report but no EMA or EMI.

Participants' alcohol outcomes and psychiatric symptomatology at 6-weeks, 12-weeks, and 6-months will be assessed to determine outcomes and feasibility/acceptability. It is hypothesized that:

  1. Individuals in PFIcope+EMI arm will report between-subjects reductions in drinking to cope, alcohol use, alcohol-related problems, and NA as compared to PNF.
  2. PFIcope+EMI will be feasible to implement and result in high rates of participant satisfaction.

Mechanisms that may underlie the efficacy of the intervention for the PFIcope+EMI group utilizing the daily EMA data will be explored. It is hypothesized that:

  1. In response to NA, participants will report an increase in coping skills utilization and decreased intent to drink at the following EMA assessment point.
  2. NA reductions and increased coping skills utilization will be related to improvements in alcohol use rates and problems at the following EMA assessment.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Rhode Island
      • Providence, Rhode Island, United States, 02906
        • Butler Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 25 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. between 18 and 25 years of age
  2. reported alcohol use at least 3x weekly over past month and at least one day per week, on average, of binge drinking (as defined as 4+ drinks/2 hours for men and 3+ drinks/2 hours for women)
  3. self-reported use of coping motive (mean of 2+ on coping subscale of MDMQ-R, indicating they drink to cope at least "some of the time")
  4. current anxiety and/or depression symptomatology (as assessed CES-D scores above cut-off for high risk for clinical depression and GAD-7 scores above cut-off for moderate to severe anxiety)
  5. owns a smartphone capable of downloading EMA app.

Exclusion Criteria:

  1. current DSM-5 diagnosis of moderate/severe substance use disorder (other than alcohol, cannabis, or nicotine) as assessed by research staff via SCID
  2. a history of psychotic disorder or current psychotic symptoms as assessed by research staff via SCID
  3. current suicidal/homicidal ideation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PFIcope+EMI
The 6-week PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported).
An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
Active Comparator: Personalized Normative Feedback (PNF)
Participants in the PNF condition will receive normative feedback only on their alcohol use.
Normative Feedback on drinking behaviors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Drinks Per Drinking Day
Time Frame: 6-week follow-up
Drinks per drinking day assessed using the Addiction Severity Index
6-week follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety Coping Drinking Motives
Time Frame: 6-week follow-up
Mean Scores on the Drinking to Cope with Anxiety subscale of the Modified Drinking Motives Questionnaire (range from 1 to 5; higher values reflect greater drinking to cope)
6-week follow-up
Depression Coping Drinking Motives
Time Frame: 6-weeks
Mean Scores on the Drinking to Cope with Depression subscale of the Modified Drinking Motives Questionnaire (range from 1 to 5; higher values reflect greater drinking to cope)
6-weeks
Positive Alcohol Outcome Expectancies
Time Frame: 6-week follow-up
Mean positive alcohol expectancies subscale of the the Comprehensive Effects of Alcohol Measure (CEOA) (range from 1 to 4; higher values reflect greater positive alcohol expectancies)
6-week follow-up
Negative Alcohol Expectancies
Time Frame: 6-weeks
Mean negative alcohol expectancies subscale of the the Comprehensive Effects of Alcohol Measure (CEOA) (range from 1 to 4; higher values reflect greater negative alcohol expectancies)
6-weeks
Alcohol-related Problems
Time Frame: 6-week follow-up
Summed total of alcohol-related problems measured using the Brief Young Adult Alcohol Consequences Questionnaire (B-YAACQ) (range is 0 to 24; higher number reflect more alcohol-related problems)
6-week follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Drinking Motives
Time Frame: 12-week follow-up
Mean Scores on the Drinking to Cope subscale of the Modified Drinking Motives Questionnaire (range from 5 to 25; higher values reflect greater drinking to cope)
12-week follow-up
Drinking Motives
Time Frame: 6-month follow-up
Mean Scores on the Drinking to Cope subscale of the Modified Drinking Motives Questionnaire (range from 5 to 25; higher values reflect greater drinking to cope)
6-month follow-up
Alcohol Outcome Expectancies
Time Frame: 12-week follow-up
The number of benefits and costs associated with changing drinking behaviors as measured by the Alcohol Outcome Expectancies Questionnaire
12-week follow-up
Alcohol Outcome Expectancies
Time Frame: 6-month follow-up
The number of benefits and costs associated with changing drinking behaviors as measured by the Alcohol Outcome Expectancies Questionnaire
6-month follow-up
Drinks Per Drinking Days
Time Frame: 6-month follow-up
Drinks per drinking day assessed using the Timeline Followback (TLFB)
6-month follow-up
Alcohol-related Problems
Time Frame: 12-week follow-up
Number of consequences of alcohol use assessed with the Rutgers Alcohol Problems Index
12-week follow-up
Alcohol-related Problems
Time Frame: 6-month follow-up
Number of consequences of alcohol use assessed with the Rutgers Alcohol Problems Index
6-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ana M Abrantes, Ph.D., Butler Hospital/Alpert Medical School of Brown University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 6, 2023

Primary Completion (Actual)

June 30, 2025

Study Completion (Actual)

June 30, 2025

Study Registration Dates

First Submitted

September 17, 2021

First Submitted That Met QC Criteria

September 29, 2021

First Posted (Actual)

October 12, 2021

Study Record Updates

Last Update Posted (Actual)

August 20, 2026

Last Update Submitted That Met QC Criteria

July 30, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2104-001
  • R34AA028572 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe